Join to View Full Profile
333 Cedar StNew Haven, CT 06510
Phone+1 203-785-4095
Fax+1 617-732-5706
Dr. Stahl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2018
Yale-New Haven Medical CenterResidency, Internal Medicine, 2014 - 2017
Hannover Medical SchoolClass of 2012
Certifications & Licensure
CT State Medical License 2017 - 2026
MA State Medical License 2021 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Venetoclax-Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC-DATAML-MSKCC Retrospective Study.Cassandre Petit, Jules Higue, Ziyad Acheaibi, Julia Gilhodes, Marie-Anne Hospital
American Journal of Hematology. 2025-05-01 - Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.Shai Shimony, Maximilian Stahl, Richard M Stone
American Journal of Hematology. 2025-05-01 - Imetelstat in myeloid malignancies: current data and future directions.Aram Bidikian, Jan P Bewersdorf, Tariq Kewan, Nikolai A Podoltsev, Maximilian Stahl
Expert Review of Anticancer Therapy. 2025-03-28
Lectures
- Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
“Time to Move On”: How Targeted Therapies Are Transforming AML CareApril 1st, 2025- TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment UpdatesJune 1st, 2024
- What Is the Best Method for Cytoreduction in Patients with Acute Myeloid Leukemia and Hyperleukocytosis?February 1st, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
